Cargando…

The Integrated Bioinformatic Assay of Genetic Expression Features and Analyses of Traditional Chinese Medicine Specific Constitution Reveal Metabolic Characteristics and Targets in Steatosis of Nonalcoholic Fatty Liver Disease

PURPOSE: In this study, our primary aim is to analyze the genetic expression feature and analyze specific Traditional Chinese medicine (TCM) constitution distribution in non-alcoholic fatty liver disease (NAFLD) and reveal the metabolic characteristic of NAFLD. MATERIALS AND METHODS: For revealing g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Chunping, Gu, Chengying, Wen, Song, He, Yanju, Yang, Sheng, Feng, Xinge, Zeng, Yipeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563782/ https://www.ncbi.nlm.nih.gov/pubmed/37822344 http://dx.doi.org/10.2147/HMER.S428161

Ejemplares similares

Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats undergoing catch-up growth
por: GU, CHENGYING, et al.
Publicado: (2015)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients
por: Wang, Qingling, et al.
Publicado: (2022)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
por: Jo, Ik Hyun, et al.
Publicado: (2023)

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice
por: Rom, Oren, et al.
Publicado: (2019)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Cyanotoxins Increase Cytotoxicity and Promote Nonalcoholic Fatty Liver Disease Progression by Enhancing Cell Steatosis
por: Niture, Suryakant, et al.
Publicado: (2023)

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
por: Ahn, Hwa Young, et al.
Publicado: (2018)

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease
por: Behari, Jaideep, et al.
Publicado: (2021)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2021)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease
por: Wu, Chutian, et al.
Publicado: (2021)

Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis
por: Mahmoudi, Ali, et al.
Publicado: (2021)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Huang, Shanzhou, et al.
Publicado: (2018)

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2017)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
por: Mukai, Takako, et al.
Publicado: (2017)

Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial
por: Soleimani, Davood, et al.
Publicado: (2020)

The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
por: Nadinskaia, Maria, et al.
Publicado: (2021)

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease
por: Li, Yuchang, et al.
Publicado: (2021)

Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice
por: Yuan, Youwen, et al.
Publicado: (2022)

Candidate genes investigation for severe nonalcoholic fatty liver disease based on bioinformatics analysis
por: Qi, Shan, et al.
Publicado: (2017)

Identification of key pathways and genes in nonalcoholic fatty liver disease using bioinformatics analysis
por: Liu, Jingqi, et al.
Publicado: (2020)

Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2020)

Hepatorenal Index by B‐Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol‐Related and Nonalcoholic Fatty Liver Disease
por: Kjaergaard, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2i9g8cm6lm1ge110v72ou1f3hl